COATSOME ® NC-21E
20. In vivo 実験
106
を 200 L 添加し、37ºC、5% CO2 濃度下で 3 時間インキュベートした。 その 後、
pDNA/
キャリア複合体を除去し、10% (v/v) FBS
培地含有培地400 L
を添 加し、さらに 21 時間培養した。細胞抽出液の調製：トランスフェクション終了後の細胞を PBS (-) 400 L で
1
回洗浄後、PBS (-) で 5 倍希釈した細胞溶解剤 300 L を添加し、15 分間室 温でインキュベートし、さらに凍結(-80ºC)
および融解(37ºC)
を3
回繰り返 した。得られた細胞溶解液を 10,000 rpm で 10 分間遠心分離し、その上清を細 胞抽出液とした。ルシフェラーゼ活性の測定：細胞抽出液 20 L をルミノメーター用試験管
(Röhren Tubes、SARSTEDT)
に採取し、これに Luciferase Assay Substrate 100 L を添加した。 ルミノメーター (EG&G BERHTOLD 製 Lumat LB 9507) で 10 秒間の発光量を測定し、レニラルシフェラーゼ活性を評価した。細胞抽出液中のタンパク質の定量：細胞抽出液 10 L に BCA Protein Assay
Kit
溶液を 200 L 添加し、37ºC、30 分間インキュベートした。 その後、マイ クロプレートリーダー (Bio-Rad 製 Model 550) にて 570 nm における吸光度 を測定した。 細胞溶解剤でBSA
を希釈したものを標準液に用いて検量線を作 成し、上記ルシフェラーゼ活性およびタンパク質濃度より相対発光量 (RLU) を 算出した。107
件でルシフェラーゼ活性およびタンパク質濃度を求め、RLU を算出した。
108
参 考 文 献
1) Rabinow B. E., Nanosuspensions in drug delivery. Nat. Rev. Drug Discov., 3, 785-796 (2004).
2) Frokjaer S., Otzen D. E., Protein drug stability: a formulation challenge. Nat. Rev. Drug Discov., 4, 298-306 (2005).
3) Pfeifer A., Verma I. M., Gene therapy: promises and problems. Annu. Rev. Genomics Hum. Genet., 2, 177-211 (2001).
4) Ciobanu B. C., Cadinoiu A. N., Popa M., Desbrieres J., Peptu C. A., Modulated release from liposomes entrapped in chitosan/gelatin hydrogels. Mater. Sci. Eng. C Mater. Biol.
Appl., 43, 383-391 (2014).
5) Pachuau L., Mazumder B., Colonic drug delivery systems based on natural
polysaccharides and their evaluation. Mini Rev. Med. Chem., 13, 1982-1991 (2013).
6) Scholtz J., Van der Colff J., Steenekamp J., Stieger N., Hamman J., More good news about polymeric plant- and algae-derived biomaterials in drug delivery systems. Curr.
Drug Targets, 15, 486-501 (2014).
7) Sadat T. M. F., Nejati-Koshki K., Akbarzadeh A., Yamchi M. R., Milani M., Zarghami N., Zeighamian V., Rahimzadeh A., Alimohammadi S., Hanifehpour Y., Joo S. W., PLGA-based nanoparticles as cancer drug delivery systems. Asian Pac. J. Cancer Prev., 15, 517-535 (2014).
8) Schweizer D., Serno T., Goepferich A., Controlled release of therapeutic antibody formats. Eur. J. Pharm. Biopharm., 88, 291-309 (2014).
9) Nishiyama N., Okazaki S., Cabral H., Miyamoto M., Kato Y., Sugiyama Y., Nishio K., Matsumura Y., Kataoka K., Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res., 63, 8977-8983 (2003).
10) Kwon G. S., Diblock copolymer nanoparticles for drug delivery. Crit. Rev. Ther. Drug Carrier Syst., 15, 481-512 (1998).
11) Al-Halafi A. M., Nanocarriers of nanotechnology in retinal diseases. Saudi. J.
Ophthalmol., 28, 304-309 (2014).
109
12) Hu L., Zhang H., Song W., An overview of preparation and evaluation sustained-release injectable microspheres. J. Microencapsul., 30, 369-382 (2013).
13) Nochi T., Yuki Y., Takahashi H., Sawada S., Mejima M., Kohda T., Harada N., Kong I.
G., Sato A., Kataoka N., Tokuhara D., Kurokawa S., Takahashi Y., Tsukada H., Kozaki S., Akiyoshi K., Kiyono H., Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat. Mater., 9, 572-578 (2010).
14) Li J. J., Zhao F., Li J., Supramolecular polymers based on cyclodextrins for drug and gene delivery. Adv. Biochem. Eng. Biotechnol., 125, 207-249 (2011).
15) 上釜兼人, 川島嘉明, 竹内洋文, 松田芳久, 最新製剤学, 廣川書店, 東京 (2011).
16) Szoka F., Papahadjopoulos D., Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc. Natl. Acad.
Sci. U. S. A., 75, 4194-4198 (1978).
17) Abra R. M., Hunt C. A., Lau D. T., Liposome disposition in vivo. VI: Delivery to the lung. J. Pharm. Sci., 73, 203-206 (1984).
18) Allen T. M., Everest J. M., Effect of liposome size and drug release properties on pharmacokinetics of encapsulated drug in rats. J. Pharmacol. Exp. Ther., 226, 539-544 (1983).
19) Bangham A. D., Lipid bilayers and biomembranes. Annu. Rev. Biochem., 41, 753-776 (1972).
20) Kimelberg H. K., Protein-liposome interactions and their relevance to the structure and function of cell membranes. Mol. Cell Biochem., 10, 171-190 (1976).
21) Garcon N., Gregoriadis G., Taylor M., Summerfield J., Mannose-mediated targeted immunoadjuvant action of liposomes. Immunology, 64, 743-745 (1988).
22) Klibanov A. L., Maruyama K., Torchilin V. P., Huang L., Amphipathic
polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett., 268, 235-237 (1990).
23) Working P. K., Newman M. S., Sullivan T., Yarrington J., Reduction of the
cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes. J. Pharmacol. Exp. Ther., 289, 1128-1133 (1999).
110
24) Cabanes A., Tzemach D., Goren D., Horowitz A. T., Gabizon A., Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. Clin. Cancer Res., 4, 499-505 (1998).
25) Harrington K. J., Mohammadtaghi S., Uster P. S., Glass D., Peters A. M., Vile R. G., Stewart J. S., Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin. Cancer Res., 7, 243-254 (2001).
26) Papahadjopoulos D., Allen T. M., Gabizon A., Mayhew E., Matthay K., Huang S. K., Lee K. D., Woodle M. C., Lasic D. D., Redemann C., et al., Sterically stabilized
liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc.
Natl. Acad. Sci. U. S. A., 88, 11460-11464 (1991).
27) Maeda H., Wu J., Sawa T., Matsumura Y., Hori K., Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release, 65, 271-284 (2000).
28) Yamada A., Taniguchi Y., Kawano K., Honda T., Hattori Y., Maitani Y., Design of folate-linked liposomal doxorubicin to its antitumor effect in mice. Clin. Cancer Res., 14, 8161-8168 (2008).
29) Maruyama K., PEG-immunoliposome. Biosci. Rep., 22, 251-266 (2002).
30) Hatakeyama H., Akita H., Maruyama K., Suhara T., Harashima H., Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo.
Int. J. Pharm., 281, 25-33 (2004).
31) Managit C., Kawakami S., Nishikawa M., Yamashita F., Hashida M., Targeted and sustained drug delivery using PEGylated galactosylated liposomes. Int. J. Pharm., 266, 77-84 (2003).
32) Maeda N., Takeuchi Y., Takada M., Sadzuka Y., Namba Y., Oku N., Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome. J. Control.
Release, 100, 41-52 (2004).
33) Schiffelers R. M., Koning G. A., ten Hagen T. L., Fens M. H., Schraa A. J., Janssen A.
P., Kok R. J., Molema G., Storm G., Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J. Control. Release, 91, 115-122 (2003).
34) Ishida O., Maruyama K., Tanahashi H., Iwatsuru M., Sasaki K., Eriguchi M., Yanagie
111
H., Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm. Res., 18, 1042-1048 (2001).
35) Gabizon A., Shmeeda H., Horowitz A. T., Zalipsky S., Tumor cell targeting of
liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv.
Drug Deliv. Rev., 56, 1177-1192 (2004).
36) 鈴木 亮, 小田雄介, 宇都口直樹, 丸山一雄, 超音波感受性リポソームを利用し た超音波がん治療システムの開発. 薬学雑誌, 130, 1665-1670 (2010).
37) Hamada T., Sato Y. T., Yoshikawa K., Nagasaki T., Reversible photoswitching in a cell-sized vesicle. Langmuir, 21, 7626-7628 (2005).
38) Needham D., Anyarambhatla G., Kong G., Dewhirst M. W., A new
temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res., 60, 1197-1201 (2000).
39) Liu Y., Li Z., Liang D., Behaviors of liposomes in a thermo-responsive poly(N-isopropylacrylamide) hydrogel. Soft Matter., 8, 4517-4523 (2012).
40) Alinaghi A., Rouini M. R., Johari D. F., Moghimi H. R., Hydrogel-embeded vesicles, as a novel approach for prolonged release and delivery of liposome, in vitro and in vivo. J.
Liposome Res., 23, 235-243 (2013).
41) Wang W., Zhang P., Shan W., Gao J., Liang W., A novel chitosan-based thermosensitive hydrogel containing doxorubicin liposomes for topical cancer therapy. J. Biomater. Sci.
Polym. Ed., 24, 1649-1659 (2013).
42) Mulik R., Kulkarni V., Murthy R. S., Chitosan-based thermosensitive hydrogel containing liposomes for sustained delivery of cytarabine. Drug Dev. Ind. Pharm., 35, 49-56 (2009).
43) Suri A., Campos R., Rackus D. G., Spiller N. J. S., Richardson C., Pålsson L. O., Kataky R., Liposome-doped hydrogel for implantable tissue. Soft Matter., 7, 7071-7077 (2011).
44) Kang J. W., Davaa E., Kim Y. T., Park J. S., A new vaginal delivery system of amphotericin B: a dispersion of cationic liposomes in a thermosensitive gel. J. Drug Target., 18, 637-644 (2010).
112
45) Ruponen M., Honkakoski P., Ronkko S., Pelkonen J., Tammi M., Urtti A., Extracellular and intracellular barriers in non-viral gene delivery. J. Control. Release, 93, 213-217 (2003).
46) Sun X., Zhang N., Cationic polymer optimization for efficient gene delivery. Mini Rev.
Med. Chem., 10, 108-125 (2010).
47) Arima H., Motoyama K., Recent findings concerning PAMAM dendrimer conjugates with cyclodextrins as carriers of DNA and RNA. Sensors, 9, 6346-6361 (2009).
48) Arima H., Motoyama K., Higashi T., Potential use of polyamidoamine dendrimer conjugates with cyclodextrins as novel carriers for siRNA. Pharmaceuticals, 5, 61-78 (2011).
49) Arima H., Motoyama K., Higashi T., Polyamidoamine dendrimer conjugates with cyclodextrins as novel carriers for DNA, shRNA and siRNA. Pharmaceutics, 4, 130-148 (2012).
50) Arima H., Motoyama K., Higashi T., Sugar-appended polyamidoamine dendrimer conjugates with cyclodextrins as cell-specific non-viral vectors. Adv. Drug Deliv. Rev., 65, 1204-1214 (2013).
51) Arima H., Motoyama K., Higashi T., Cyclodextrin/dendrimer conjugates as DNA and oligonucleotide carriers. Curr. Top. Med. Chem., 14, 465-477 (2014).
52) Arima H., Arizono M., Higashi T., Yoshimatsu A., Ikeda H., Motoyama K., Hattori K., Takeuchi T., Hirayama F., Uekama K., Potential use of folate-polyethylene glycol (PEG)-appended dendrimer (G3) conjugate with -cyclodextrin as DNA carriers to tumor cells. Cancer Gene Ther., 19, 358-366 (2012).
53) Arima H., Yoshimatsu A., Ikeda H., Ohyama A., Motoyama K., Higashi T., Tsuchiya A., Niidome T., Katayama Y., Hattori K., Takeuchi T., Folate-PEG-appended dendrimer conjugate with -cyclodextrin as a novel cancer cell-selective siRNA delivery carrier.
Mol. Pharm., 9, 2591-2604 (2012).
54) Arima H., Yamashita S., Mori Y., Hayashi Y., Motoyama K., Hattori K., Takeuchi T., Jono H., Ando Y., Hirayama F., Uekama K., In vitro and in vivo gene delivery mediated by lactosylated dendrimer/-cyclodextrin conjugates (G2) into hepatocytes. J. Control.
Release, 146, 106-117 (2010).
113
55) Hayashi Y., Mori Y., Higashi T., Motoyama K., Jono H., Sah D. W., Ando Y., Arima H., Systemic delivery of transthyretin siRNA mediated by lactosylated
dendrimer/-cyclodextrin conjugates into hepatocyte for familial amyloidotic polyneuropathy therapy. Amyloid, 19 Suppl 1, 47-49 (2012).
56) Hayashi Y., Mori Y., Yamashita S., Motoyama K., Higashi T., Jono H., Ando Y., Arima H., Potential use of lactosylated dendrimer (G3)/-cyclodextrin conjugates as
hepatocyte-specific siRNA carriers for the treatment of familial amyloidotic polyneuropathy. Mol. Pharm., 9, 1645-1653 (2012).
57) Hayashi Y., Higashi T., Motoyama K., Mori Y., Jono H., Ando Y., Arima H., Design and evaluation of polyamidoamine dendrimer conjugate with PEG, -cyclodextrin and lactose as a novel hepatocyte-selective gene carrier in vitro and in vivo. J. Drug Target., 21, 487-496 (2013).
58) Allen T. M., Cullis P. R., Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev., 65, 36-48 (2013).
59) Harada A., Preparation and structures of supramolecules between cyclodextrins and polymers. Coord. Chem. Rev., 148, 115-133 (1996).
60) Harada A., Li J., Suzuki S., Kamachi M., Complex formation between polyisobutylene and cyclodextrin : Inversion of chain-length selectivity between b-cyclidextrin and
-cyclodextrin. Macromolecules, 26, 5267-5268 (1993).
61) Harada A., Kamachi M., Complex formation between poly(ethylene glycol) and
-cyclodextrin. Macromolecules, 23, 2821-2823 (1990).
62) Harada A., Okada M., Li J., Kamachi M., Preparation and characterization of inclusion complexes of poly(propylene glycol) with cyclodextrins. Macromolecules, 28,
8406-8411 (1995).
63) Harada A., Li J., Kamachi M., Double-standed inclusion complexes of cyclodextrin threaded on poly(ethylene glycol). Nature, 370, 126-128 (1994).
64) Harada A., Li J., Kamachi M., The molecular necklace : A rotaxane containing many threaded -cyclodextrin. Nature, 356, 325-327 (1992).
65) Higashi T., Motoyama K., Arima H., Cyclodextrin-based polyrotaxanes and polypseudorotaxanes as drug delivery carriers. J. Drug Del. Sci. Tech., 23, 523-529
114 (2013).
66) Jiao H., Goh S. H., Valiyaveettil S., Inclusion complexes of single-C60-end-capped poly(ethylene oxide) with cyclodextrins. Macromolecules, 35, 1399-1402 (2002).
67) Higashi T., Hirayama F., Arima H., Uekama K., Polypseudorotaxanes of pegylated insulin with cyclodextrins : Application to sustained release system. Bioorg. Med. Chem.
Lett., 17, 1871-1874 (2007).
68) Higashi T., Hirayama F., Misumi S., Arima H., Uekama K., Design and evaluation of polypseudorotaxanes of pegylated insulin with cyclodextrins as sustained release system. Biomaterials, 29, 3866-3781 (2008).
69) Higashi T., Hirayama F., Misumi S., Motoyama K., Arima H., Uekama K.,
Polypseudorotaxane formation of randomly-pegylated insulin with cyclodextrins: slow release and resistance to enzymatic degradation. Chem. Pharm. Bull., 57, 541-544 (2009).
70) Higashi T., Hirayama F., Yamashita S., Misumi S., Arima H., Uekama K., Slow-release system of pegylated lysozyme utilizing formation of polypseudorotaxanes with
cyclodextrins. Int. J. Pharm., 374, 26-32 (2009).
71) Zhang L., Lu J., Jin Y., Qiu L., Folate-conjugated b-cyclodextrin-based polymeric micelles with enhanced doxorubicin antitumor efficacy. Colloids Surf. B Biointerfaces, 122, 260-269 (2014).
72) Gidwani B., Vyas A., Formulation, characterization and evaluation of
cyclodextrin-complexed bendamustine-encapsulated PLGA nanospheres for sustained delivery in cancer treatment. Pharm. Dev. Technol., 1-11 (2014).
73) Namgung R., Lee M. Y., Kim J., Jang Y., Lee B. H., Kim I. S., Sokkar P., Rhee Y. M., Hoffman A. S., Kim W. J., Poly-cyclodextrin and poly-paclitaxel nano-assembly for anticancer therapy. Nat. Commun., 5, 3702 (2014).
74) Motoyama K., Nakashima Y., Aramaki Y., Hirayama F., Uekama K., Arima H., In vitro gene delivery mediated by asialofetuin-appended cationic liposomes associated with
-cyclodextrin into hepatocytes. J. Drug Deliv., 2011, 476137 (2011).
75) Hagiwara Y., Arima H., Hirayama F., Uekama K., Prolonged retention of doxorubicin in
115
tumor cells by encapsulation of -cyclodextrin complex in pegylated liposomes. J. Incl.
Phenom. Macrocycl. Chem., 56, 65-68 (2006).
76) Puskas I., Csempesz F., Influence of cyclodextrins on the physical stability of DPPC-liposomes. Colloids Surf. B Biointerfaces, 58, 218-224 (2007).
77) Harada A., Li J., Kamachi M., Preparation and properties of inclusion complexes of poly(ethylene glycol) with -cyclodextrin. Macromolecules, 26, 5698-5703 (1993).
78) Irie T., Otagiri M., Sunada M., Uekama K., Ohtani Y., Yamada Y., Sugiyama Y., Cyclodextrin-induced hemolysis and shape changes of human erythrocytes in vitro. J.
Pharmacobiodyn., 5, 741-744 (1982).
79) Ohtani Y., Irie T., Uekama K., Fukunaga K., Pitha J., Differential effects of -, b- and
-cyclodextrins on human erythrocytes. Eur. J. Biochem., 186, 17-22 (1989).
80) Irie T., Uekama K., Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci., 86, 147-162 (1997).
81) 宮嶋孝一郎, 齋藤博幸, 中垣正幸, シクロデキストリンと脂質膜との相互作用. 日本化学会誌, 3, 306-312 (1987).
82) Mayer L. D., Bally M. B., Cullis P. R., Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim. Biophys. Acta, 857, 123-126 (1986).
83) Sabeti B., Noordin M. I., Mohd S., Hashim R., Dahlan A., Javar H. A., Development and characterization of liposomal doxorubicin hydrochloride with palm oil. Biomed. Res.
Int., 2014, 765426 (2014).
84) Becheri A., Nostro P. L., Ninham B. W., Baglioni P., The curious world of
polypseudorotaxanes：cyclodextrins as probes of water structure. J. Phys. Chem. B, 107, 3979-3987 (2003).
85) Lee D., Kim J. W., Kim B. G., A new parameter to control heat transport in nanofluids:
surface charge state of the particle in suspension. J. Phys. Chem. B, 110, 4323-4328 (2006).
86) Jiang J., Oberdörster G., Biswa P., Characterization of size, surface charge, and agglomeration state of nanoparticle dispersions for toxicological studies. J. Nanopart.
Res., 11, 77-89 (2009).
116
87) He C., Hu Y., Yin L., Tang C., Yin C., Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials, 31, 3657-3666 (2010).
88) Lu J., Shin I. C., Nojima S., Tonelli A. E., Formation and characterization of the inclusion compounds between poly(-caprolactone)-poly(ethylene oxide)-poly
(-caprolactone) triblock copolymer and - and -cyclodextrin. Polymer, 41, 5871-5883 (2001).
89) 原田一明, シクロデキストリン超分子の構造化学. アイピーシー, 東京 (2000).
90) Takeo K., Kuge T., Complexes of starchy materials with organic compound part III.
A-ray studies on amylose and cyclodextrin complexes. Arg. Biol. Chem., 33, 1174-1180 (1969).
91) Takeo K., Kuge T., Complexes of starchy materials with organic compound part IV.
X-ray diffraction of -cyclodextrin complexes. Agr. Biol. Chem., 34, 568-574 (1970).
92) Topchieva I. N., Tonelli A. E., Panova I. G., Matuchina E. V., Kalashnikov F. A., Gerasimov V. I., Rusa C. C., Rusa M., Hunt M. A., Two-phase channel structures based on -cyclodextrin-polyethylene glycol inclusion complexes. Langmuir, 20, 9036-9043 (2004).
93) Toropainen T., Heikkila T., Leppanen J., Matilainen L., Velaga S., Jarho P., Carlfors J., Lehto V. P., Jarvinen T., Jarvinen K., Crystal structure changes of -cyclodextrin after the SEDS process in supercritical carbon dioxide affect the dissolution rate of complexed budesonide. Pharm. Res., 24, 1058-1066 (2007).
94) Harada A., Li J., Kamachi M., Preparation and properties of inclusion complexes of poly (ethylene glycol) with -cyclodextrin. Macromolecules, 26, 5698-5703 (1993).
95) Harris J. M., Chess R. B., Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov., 2, 214-221 (2003).
96) Rudorf S., Radler J. O., Self-assembly of stable monomolecular nucleic acid lipid particles with a size of 30 nm. J. Am. Chem. Soc., 134, 11652-11658 (2012).
97) Higuchi T., Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid materices. J. Pharm. Sci., 52, 1145-1149
117 (1963).
98) Hixson A. W., Crowell J. H., Dependence of reaction velocity upon surface and agitation (I) theoretical consideration. Ind. Eng. Chem., 23, 923-931 (1931).
99) Palanisamy M., Khanam J., Cellulose-based matrix microspheres of prednisolone inclusion complex: preparation and characterization. AAPS PharmSciTech, 12, 388-400 (2011).
100) Buning H., Nicklin S. A., Perabo L., Hallek M., Baker A. H., AAV-based gene transfer.
Curr. Opin. Mol. Ther., 5, 367-375 (2003).
101) Croyle M. A., Roessler B. J., Hsu C. P., Sun R., Amidon G. L., b-Cyclodextrins enhance adenoviral-mediated gene delivery to the intestine. Pharm. Res., 15, 1348-1355 (1998).
102) Lawrencia C., Mahendran R., Esuvaranathan K., Transfection of urothelial cells using methyl-b-cyclodextrin solubilized cholesterol and dotap. Gene Ther., 8, 760-768 (2001).
103) Roessler B. J., Bielinska A. U., Janczak K., Lee I., Baker J. R., Substituted b-cyclodextrins interact with PAMAM dendrimer-DNA complexes and modify transfection efficiency. Biochem. Biophys. Res. Commun., 283, 124-129 (2001).
104) Davis M. E., Pun S. H., Bellocq N. C., Reineke T. M., Popielarski S. R., Mishra S., Heidel J. D., Self-assembling nucleic acid delivery vehicles via linear, water-soluble, cyclodextrin-containing polymers. Curr. Med. Chem., 11, 179-197 (2004).
105) Huang H., Tang G., Wang Q., Li D., Shen F., Zhou J., Yu H., Two novel non-viral gene delivery vectors: low molecular weight polyethylenimine cross-linked by
(2-hydroxypropyl)-b-cyclodextrin or (2-hydroxypropyl)--cyclodextrin. Chem.
Commun., 42, 2382-2384 (2006).
106) Bellocq N. C., Pun S. H., Jensen G. S., Davis M. E., Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug.
Chem., 14, 1122-1132 (2003).
107) Arima H., Kihara F., Hirayama F., Uekama K., Enhancement of gene expression by polyamidoamine dendrimer conjugates with -, b-, and -cyclodextrins. Bioconjug.
Chem., 12, 476-484 (2001).
108) Khouri S., Tam K. C., Complexation between -cyclodextrin and PEGylated-PAMAM
118
dendrimers at low and high pH values. Langmuir, 26, 17969-17974 (2010).
109) Yang C., Wang X., Li H., Goh S. H., Li J., Synthesis and characterization of polyrotaxanes consisting of cationic -cyclodextrins threaded on poly[(ethylene oxide)-ran-(propylene oxide)] as gene carriers. Biomacromolecules, 8, 3365-3374 (2007).
110) Yang C., Li J., Thermoresponsive behavior of cationic polyrotaxane composed of multiple pentaethylenehexamine-grafted -cyclodextrins threaded on poly(propylene oxide)-poly(ethylene oxide)-poly(propylene oxide) triblock copolymer. J. Phys. Chem.
B, 113, 682-690 (2009).
111) Zhang W., Chen Z., Song X., Si J., Tang G., Low generation polypropylenimine dendrimer graft b-cyclodextrin: an efficient vector for gene delivery system. Technol.
Cancer Res. Treat., 7, 103-108 (2008).
112) Ooya T., Yamashita A., Kurisawa M., Sugaya Y., Maruyama A., Yui N., Effects of polyrotaxane structure on polyion comlexation with DNA. Sci. Technol. Adv. Mater., 5, 363-369 (2004).
113) Ooya T., Choi H. S., Yamashita A., Yui N., Sugaya Y., Kano A., Maruyama A., Akita H., Ito R., Kogure K., Harashima H., Biocleavable polyrotaxane-plasmid DNA polyplex for enhanced gene delivery. J. Am. Chem. Soc., 128, 3852-3853 (2006).
114) Tamura A., Yui N., Cellular internalization and gene silencing of siRNA polyplexes by cytocleavable cationic polyrotaxanes with tailored rigid backbones. Biomaterials, 34, 2480-2491 (2013).
115) Tamura A., Yui N., Threaded macromolecules as a versatile framework for biomaterials.
Chem. Commun., 50, 13433-13446 (2014).
116) Yamada Y., Hashida M., Nomura T., Harashima H., Yamasaki Y., Kataoka K., Yamashita A., Katoono R., Yui N., Different mechanisms for nanoparticle formation between pDNA and siRNA using polyrotaxane as the polycation. Chemphyschem, 13, 1161-1165 (2012).
117) Yamada Y., Nomura T., Harashima H., Yamashita A., Katoono R., Yui N., Intranuclear DNA release is a determinant of transfection activity for a non-viral vector:
biocleavable polyrotaxane as a supramolecularly dissociative condenser for efficient
119
intranuclear DNA release. Biol. Pharm. Bull., 33, 1218-1222 (2010).
118) Yamada Y., Nomura T., Harashima H., Yamashita A., Yui N., Post-nuclear gene delivery events for transgene expression by biocleavable polyrotaxanes. Biomaterials, 33, 3952-3958 (2012).
119) Zhou Y., Wang H., Wang C., Li Y., Lu W., Chen S., Luo J., Jiang Y., Chen J.,
Receptor-mediated, tumor-targeted gene delivery using folate-terminated polyrotaxanes.
Mol. Pharm., 9, 1067-1076 (2012).
120) Hu Y., Tang G., Liu J., Cheng W., Yue Y., Li J., Zhang P., FGF receptor-mediated gene delivery using ligands coupled to PEI-b-CyD. J. Biomed. Biotechnol., 2012, 989235 (2012).
121) Li Z., Yin H., Zhang Z., Liu K. L., Li J., Supramolecular anchoring of DNA polyplexes in cyclodextrin-based polypseudorotaxane hydrogels for sustained gene delivery.
Biomacromolecules, 13, 3162-3172 (2012).
122) Ping Y., Liu C., Zhang Z., Liu K. L., Chen J., Li J., Chitosan-graft-(PEI-b-cyclodextrin) copolymers and their supramolecular PEGylation for DNA and siRNA delivery.
Biomaterials, 32, 8328-8341 (2011).
123) Guo J., Ogier J. R., Desgranges S., Darcy R., O'Driscoll C., Anisamide-targeted
cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice. Biomaterials, 33, 7775-7784 (2012).
124) Silva O. F., Fernandez M. A., Pennie S. L., Gil R. R., de Rossi R. H., Synthesis and characterization of an amphiphilic cyclodextrin, a micelle with two recognition sites.
Langmuir, 24, 3718-3726 (2008).
125) Diaz-Moscoso A., Vercauteren D., Rejman J., Benito J. M., Ortiz Mellet C., De Smedt S.
C., Fernandez J. M., Insights in cellular uptake mechanisms of pDNA-polycationic amphiphilic cyclodextrin nanoparticles (CDplexes). J. Control. Release, 143, 318-325 (2010).
126) Diaz-Moscoso A., Guilloteau N., Bienvenu C., Mendez-Ardoy A., Blanco J. L., Benito J.
M., Le Gourrierec L., Di Giorgio C., Vierling P., Defaye J., Mellet C. O., Fernandez J.
M., Mannosyl-coated nanocomplexes from amphiphilic cyclodextrins and pDNA for site-specific gene delivery. Biomaterials, 32, 7263-7273 (2011).
120
127) Symens N., Mendez-Ardoy A., Diaz-Moscoso A., Sanchez-Fernandez E., Remaut K., Demeester J., Fernandez J. M., De Smedt S. C., Rejman J., Efficient transfection of hepatocytes mediated by mRNA complexed to galactosylated cyclodextrins. Bioconjug.
Chem., 23, 1276-1289 (2012).
128) Li J. M., Wang Y. Y., Zhang W., Su H., Ji L. N., Mao Z. W., Low-weight
polyethylenimine cross-linked 2-hydroxypopyl-b-cyclodextrin and folic acid as an efficient and nontoxic siRNA carrier for gene silencing and tumor inhibition by VEGF siRNA. Int. J. Nanomedicine, 8, 2101-2117 (2013).
129) Huang H., Cao D., Qin L., Tian S., Liang Y., Pan S., Feng M., Dilution-stable PAMAM G1-grafted polyrotaxane supermolecules deliver gene into cells through a
caveolae-dependent pathway. Mol. Pharm., 11, 2323-2333 (2014).
130) Anno T., Higashi T., Motoyama K., Hirayama F., Uekama K., Arima H., Possible enhancing mechanisms for gene transfer activity of glucuronylglucosyl-b-cyclodextrin/
dendrimer conjugate. Int. J. Pharm., 426, 239-247 (2012).
131) Anno T., Higashi T., Motoyama K., Hirayama F., Uekama K., Arima H., Potential use of glucuronylglucosyl-b-cyclodextrin/dendrimer conjugate (G2) as a DNA carrier in vitro and in vivo. J Drug Target., 20, 272-280 (2012).
132) Abdelwahab A. F., Ohyama A., Higashi T., Motoyama K., Khaled K. A., Sarhan H. A., Hussein A. K., Arima H., Preparation and evaluation of polyamidoamine dendrimer conjugate with glucuronylglucosyl-b-cyclodextrin (G3) as a novel carrier for siRNA. J Drug Target., 22, 927-934 (2014).
133) Anno T., Higashi T., Hayashi Y., Motoyama K., Jono H., Ando Y., Arima H., Potential use of glucuronylglucosyl-b-cyclodextrin/dendrimer conjugate (G2) as a siRNA carrier for the treatment of familial amyloidotic polyneuropathy. J. Drug Target., 22, 883-890 (2014).
134) Wada K., Arima H., Tsutsumi T., Chihara Y., Hattori K., Hirayama F., Uekama K., Improvement of gene delivery mediated by mannosylated dendrimer/-cyclodextrin conjugates. J. Control. Release, 104, 397-413 (2005).
135) Wada K., Arima H., Tsutsumi T., Hirayama F., Uekama K., Enhancing effects of galactosylated dendrimer/-cyclodextrin conjugates on gene transfer efficiency. Biol.
Pharm. Bull., 28, 500-505 (2005).
121
136) Arima H., Chihara Y., Arizono M., Yamashita S., Wada K., Hirayama F., Uekama K., Enhancement of gene transfer activity mediated by mannosylated
dendrimer/-cyclodextrin conjugate (generation 3, G3). J. Control. Release, 116, 64-74 (2006).
137) Motoyama K., Mitsuyasu R., Akao C., Tanaka T., Ohyama A., Sato N., Higashi T., Arima H., Design and evaluation of thioalkylated mannose-modified dendrimer (G3)/-cyclodextrin conjugates as antigen-presenting cell-selective siRNA carriers.
AAPS J., 16, 1298-1308 (2014).
138) Akao C., Tanaka T., Onodera R., Ohyama A., Sato N., Motoyama K., Higashi T., Arima H., Potential use of fucose-appended dendrimer/-cyclodextrin conjugates as NF-B decoy carriers for the treatment of lipopolysaccharide-induced fulminant hepatitis in mice. J. Control. Release, 193, 35-41 (2014).
139) Wagner E., Cotten M., Foisner R., Birnstiel M. L., Transferrin-polycation-DNA complexes: the effect of polycations on the structure of the complex and DNA delivery to cells. Proc. Natl. Acad. Sci. U. S. A., 88, 4255-4259 (1991).
140) Grosse S., Aron Y., Thevenot G., Francois D., Monsigny M., Fajac I., Potocytosis and cellular exit of complexes as cellular pathways for gene delivery by polycations. J.
Gene Med., 7, 1275-1286 (2005).
141) Ogris M., Brunner S., Schuller S., Kircheis R., Wagner E., PEGylated
DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther., 6, 595-605 (1999).
142) Rensen P. C., Sliedregt L. A., Ferns M., Kieviet E., van Rossenberg S. M., van Leeuwen S. H., van Berkel T. J., Biessen E. A., Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo. J. Biol. Chem., 276, 37577-37584 (2001).
143) Raspaud E., Pelta J., de Frutos M., Livolant F., Solubility and charge inversion of complexes of DNA and basic proteins. Phys. Rev. Lett., 97, 068103 (2006).
144) Avall-Lundqvist E., Economidou-Karaoglou A., Sjovall K., Lans M., Taper H. S., Roberfroid M., Eneroth P., Serum alkaline DNase activity in normal or nonhospitalised individuals. Clin. Chim. Acta, 185, 35-43 (1989).